Combined Behavioral and Drug Treatment of Overactive Bladder in Men
Combined Behavioral and Drug Treatment of Overactive Bladder in Men
The primary aim of this project is to evaluate the effectiveness of combined behavioral +
 drug therapy compared to behavioral treatment alone and drug therapy alone as a way to
 improve outcomes in the treatment of OAB symptoms in men. We hypothesize that combined
 therapy will result in better outcomes than either behavioral or drug therapy alone. The
 second aim is to compare two methods of implementing combined therapy: simultaneously as
 initial therapy vs. stepped therapy, in which therapies are combined following initial
 behavioral or drug therapy alone. The third aim is to examine the costs and
 cost-effectiveness of combined behavioral + drug therapy compared to behavioral or drug
 therapy alone.
Overactive bladder (OAB) is a very common, distressing condition that manifests as bothersome
 symptoms of urgency, frequent urination, urge incontinence, and nocturia, and impacts the
 lives of millions of men. OAB symptoms are most often treated with pharmacologic therapies
 (alpha-blocking agents and/or antimuscarinic agents) or behavioral treatments. Although drug
 therapies (even combined drug therapies) and behavioral treatments reduce OAB symptoms, few
 patients are completely cured with either treatment alone. Therefore, there is a need to
 improve interventions for this common problem. The primary purpose of this study is to test
 the effectiveness of combining behavioral treatment and drug therapy as a way to improve
 outcomes in the treatment of OAB symptoms in men. This is a 3-site, 2-stage, 3-arm randomized
 clinical trial of behavioral treatment, drug therapy, and combined drug + behavioral therapy
 for men with OAB, to examine the efficacy of combined therapy and whether it yields higher
 success rates than either therapy alone. 204 men with OAB were enrolled and randomized to 1)
 drug therapy alone followed by combined therapy, 2) behavioral treatment alone followed by
 combined therapy, or 3) combined therapy as initial treatment.
Inclusion Criteria:

 1. Community-dwelling men

 2. Age 40 years or older

 3. Patient-reported urgency and 9.0 or more voids per 24-hour day (on average) on the
 7-day baseline bladder diary.

 Exclusion Criteria:

 1. Urinary flow rate < 8.0 mL/sec on a void greater than 125 ml.

 2. Post-void residual volume greater than 150 mL (based on bladder ultrasound after
 voiding in the presence of a normal urge to urinate).

 3. Urinary tract infection (defined as growth of greater than 10,000 colonies per ml of a
 urinary pathogen on urine culture). Patients will be referred for treatment with
 antibiotics and may be enrolled if OAB symptoms persist after the infection is
 resolved.

 4. Transurethral resection of the prostate (TURP), simple prostatectomy, or other benign
 prostatic hypertrophy (BPH) related surgery within the past 5 years.

 5. Current active treatment for prostate cancer.

 6. History of radical prostatectomy.

 7. Previous artificial urinary sphincter, sling procedure, bladder-injection of botulinum
 toxin, or implanted sacral neuromodulation device.

 8. Poorly controlled diabetes (glycosylated hemoglobin >9.0 within last 3 months).
 Subjects with poorly controlled diabetes will be offered enrollment if the OAB
 symptoms persist after the diabetes is controlled appropriately.

 9. Hematuria on microscopic examination in the absence of infection. A urologic
 consultation will be recommended and enrollment will depend on clearance by a
 urologist and agreement by the Site PI that entry into the treatment protocol is not
 contraindicated.

 10. Any unstable medical condition (particularly: cancers under active treatment,
 decompensated congestive heart failure, history of malignant arrhythmias, unstable
 angina, diagnosed by history or physical exam).

 11. Neurologic conditions such as Parkinson's, spinal cord injury, multiple sclerosis, or
 myasthenia gravis.

 12. Impaired mental status. Patients who screen as probable dementia on the Mini-Cog.

 13. Contraindications to the study drugs (tolterodine and tamsulosin) including history of
 postural hypotension with syncope, history of acute urinary retention requiring
 catheterization, narrow angle glaucoma, or history of gastric retention.

 14. Hypersensitivity to tolterodine or tamsulosin.

 15. Current use of an alpha blocker agent. Evaluation will be delayed until the drug has
 been discontinued for 2 weeks.

 16. Current use of an anti-muscarinic agent for OAB. Evaluation will be delayed until the
 drug has been discontinued for 2 weeks.

 17. If on a diuretic, dose has not been stable for at least 4 weeks.

 18. If taking dutasteride or finasteride, dose has not been stable for at least 6 months.

 19. If on an antibiotic for prostatitis. Patients will be offered re-evaluation if OAB
 symptoms persist when antibiotics are completed.

 20. Full course of behavioral training.